GlobeImmune, which is developing therapeutic drugs for pancreatic cancer and hepatitis B and C, withdrew its plans for an initial public offering on Thursday citing poor market conditions. The Louisville, CO-based company was founded in 1995 and last updated its filing on September 5, 2012. Wells Fargo Securities and Piper Jaffray were set to be the joint bookrunners on the deal.
